JP2019529336A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529336A5
JP2019529336A5 JP2018566490A JP2018566490A JP2019529336A5 JP 2019529336 A5 JP2019529336 A5 JP 2019529336A5 JP 2018566490 A JP2018566490 A JP 2018566490A JP 2018566490 A JP2018566490 A JP 2018566490A JP 2019529336 A5 JP2019529336 A5 JP 2019529336A5
Authority
JP
Japan
Prior art keywords
seq
disease
amino acid
acid sequence
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018566490A
Other languages
English (en)
Japanese (ja)
Other versions
JP7029415B2 (ja
JP2019529336A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/067067 external-priority patent/WO2018011073A1/en
Publication of JP2019529336A publication Critical patent/JP2019529336A/ja
Priority to JP2021164366A priority Critical patent/JP7244600B2/ja
Publication of JP2019529336A5 publication Critical patent/JP2019529336A5/ja
Application granted granted Critical
Publication of JP7029415B2 publication Critical patent/JP7029415B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018566490A 2016-07-12 2017-07-07 過リン酸化タウに特異的な抗体およびその使用方法 Active JP7029415B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021164366A JP7244600B2 (ja) 2016-07-12 2021-10-05 過リン酸化タウに特異的な抗体およびその使用方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
DKPA201600416 2016-07-12
DKPA201600416 2016-07-12
DKPA201700008 2017-01-04
DKPA201700008 2017-01-04
DKPA201700005 2017-01-04
DKPA201700005 2017-01-04
DKPA201700179 2017-03-14
DKPA201700179 2017-03-14
PCT/EP2017/067067 WO2018011073A1 (en) 2016-07-12 2017-07-07 Antibodies specific for hyperphosphorylated tau and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021164366A Division JP7244600B2 (ja) 2016-07-12 2021-10-05 過リン酸化タウに特異的な抗体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2019529336A JP2019529336A (ja) 2019-10-17
JP2019529336A5 true JP2019529336A5 (enExample) 2021-11-18
JP7029415B2 JP7029415B2 (ja) 2022-03-03

Family

ID=60941665

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018566490A Active JP7029415B2 (ja) 2016-07-12 2017-07-07 過リン酸化タウに特異的な抗体およびその使用方法
JP2021164366A Active JP7244600B2 (ja) 2016-07-12 2021-10-05 過リン酸化タウに特異的な抗体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021164366A Active JP7244600B2 (ja) 2016-07-12 2021-10-05 過リン酸化タウに特異的な抗体およびその使用方法

Country Status (41)

Country Link
US (6) US10472415B2 (enExample)
EP (2) EP3878864A1 (enExample)
JP (2) JP7029415B2 (enExample)
KR (1) KR102551971B1 (enExample)
CN (2) CN109618556B (enExample)
AU (2) AU2017295608B2 (enExample)
BR (1) BR112018004916A2 (enExample)
CA (1) CA3027561A1 (enExample)
CL (1) CL2019000082A1 (enExample)
CO (1) CO2018014325A2 (enExample)
CY (1) CY1123995T1 (enExample)
DK (1) DK3484916T3 (enExample)
DO (1) DOP2018000281A (enExample)
EC (1) ECSP19005417A (enExample)
ES (1) ES2862427T3 (enExample)
GE (1) GEP20217222B (enExample)
HR (1) HRP20210522T1 (enExample)
HU (1) HUE053679T2 (enExample)
IL (1) IL263530B2 (enExample)
JO (1) JOP20180117B1 (enExample)
LT (1) LT3484916T (enExample)
MA (2) MA56165A (enExample)
MX (1) MX2019000476A (enExample)
MY (1) MY197836A (enExample)
NI (1) NI201900003A (enExample)
NZ (1) NZ748983A (enExample)
PE (1) PE20190227A1 (enExample)
PH (1) PH12018502613B1 (enExample)
PL (1) PL3484916T3 (enExample)
PT (1) PT3484916T (enExample)
RS (1) RS61646B1 (enExample)
RU (1) RU2760875C1 (enExample)
SG (1) SG11201811015RA (enExample)
SI (1) SI3484916T1 (enExample)
SM (1) SMT202100194T1 (enExample)
SV (1) SV2019005807A (enExample)
TN (1) TN2018000419A1 (enExample)
TW (1) TWI747922B (enExample)
UA (1) UA124104C2 (enExample)
WO (1) WO2018011073A1 (enExample)
ZA (1) ZA201808329B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2767532T3 (en) 2012-12-21 2016-09-12 Nat Inst For Quantum And Radiological Science And Tech New connection for reproduction of tau protein heavy in the brain.
NZ775762A (en) 2015-06-05 2025-02-28 Genentech Inc Anti-tau antibodies and methods of use
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
PH12018502613B1 (en) 2016-07-12 2023-02-01 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
UA128383C2 (uk) 2016-12-07 2024-07-03 Дженентек, Інк. Антитіло до тау-білка та спосіб його застосування
MX2019006330A (es) 2016-12-07 2019-09-26 Genentech Inc Anticuerpos anti-tau y metodos de uso.
CN110267985B (zh) * 2017-01-04 2023-05-23 H.隆德贝克有限公司 用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体
SG11201907422RA (en) 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
AU2018352308B2 (en) 2017-10-16 2025-06-05 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
WO2019149798A1 (en) * 2018-02-01 2019-08-08 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
CA3093200A1 (en) * 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
TW201946624A (zh) 2018-05-09 2019-12-16 新旭生技股份有限公司 雜芳基化合物及其用途
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
US12365724B2 (en) 2018-12-10 2025-07-22 New York University Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
CN113748343A (zh) 2019-03-28 2021-12-03 H.隆德贝克有限公司 pS396测定用于诊断TAU蛋白病的用途
JP7181438B2 (ja) 2019-08-06 2022-11-30 アプリノイア セラピューティクス リミテッド 病理学的タウ種に結合する抗体及びその使用
CN114728071B (zh) 2019-11-13 2024-12-06 新旭生技股份有限公司 用于降解tau蛋白聚集体的化合物及其用途
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
US20250258180A1 (en) 2021-07-27 2025-08-14 Stand Therapeutics Co., Ltd. Peptide tag and nucleic acid encoding same
US12129302B2 (en) * 2021-08-25 2024-10-29 Ibio, Inc. Anti-CD-25 antibody
WO2025090817A1 (en) * 2023-10-24 2025-05-01 Janssen Pharmaceuticals, Inc. Tau active functional assays

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0486622T3 (da) 1989-08-09 1999-07-19 Rhomed Inc Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
DK0618968T3 (da) 1991-12-06 2000-04-10 Max Planck Gesellschaft Midler til diagnostisering og behandling af Alzheimer's sygdom
WO1994019935A1 (en) 1993-03-09 1994-09-15 Genzyme Corporation Isolation of components of interest from milk
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
WO2000046147A2 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
MXPA02000962A (es) 1999-07-29 2002-07-02 Medarex Inc Anticuerpos monoclonales humanos para her2/neu.
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US20030162230A1 (en) 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
AT500379B8 (de) * 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
WO2007019273A2 (en) 2005-08-04 2007-02-15 Albert Einstein College Of Medicine Of Yeshiva University Phosphorylation of tau by abl
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル.エル.シー. Hco32およびhco27、ならびに関連実施例
EP2527369A3 (en) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
CN106390107B (zh) 2009-06-10 2019-12-31 纽约大学 病理tau蛋白的免疫靶向
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
MY164376A (en) 2010-10-07 2017-12-15 Univ Leuven Kath Phosphospecific antibodies recognizing tau
CA2813493C (en) 2010-10-11 2019-07-09 University Of Zurich Human anti-tau antibodies
JP6457263B2 (ja) * 2011-05-20 2019-01-23 オリゴメリックス インコーポレイテッド タウプロテアーゼ組成物および使用方法
KR101981351B1 (ko) * 2011-10-07 2019-09-02 에이씨 이뮨 에스.에이. 타우를 인식하는 포스포특이적 항체
RU2644242C2 (ru) 2012-04-05 2018-02-08 Ац Иммуне С.А. Гуманизированное тау-антитело
SG10201708959WA (en) 2012-07-03 2017-11-29 Univ Washington Antibodies to tau
NZ630542A (en) 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
WO2014170549A1 (en) 2013-04-16 2014-10-23 Glykos Finland Oy A method for generating induced pluripotent stem cells
GB201312226D0 (en) * 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
US10472514B2 (en) 2014-01-23 2019-11-12 Asahi Kasei Kabushiki Kaisha Block copolymer composition and adhesive composition
CN107073297B (zh) 2014-07-08 2021-09-14 纽约大学 Tau显像配体和其在Tau蛋白病的诊断和治疗中的用途
JO3711B1 (ar) * 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
PH12018502613B1 (en) 2016-07-12 2023-02-01 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CN110267985B (zh) 2017-01-04 2023-05-23 H.隆德贝克有限公司 用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体
US10934438B2 (en) 2017-04-27 2021-03-02 Axalta Coating Systems Ip Co., Llc Coatings and methods for using and producing the same

Similar Documents

Publication Publication Date Title
JP2019529336A5 (enExample)
JP7539446B2 (ja) 病理学的タウタンパク質の免疫学的標的化方法
JP7244600B2 (ja) 過リン酸化タウに特異的な抗体およびその使用方法
Bussière et al. Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Aβ immunotherapy on their clearance
Sigurdsson Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies
Schroeder et al. Tau-directed immunotherapy: a promising strategy for treating Alzheimer’s disease and other tauopathies
RU2645259C2 (ru) Терапия и диагностика на основе белков тау-опосредуемой патологии при болезни альцгеймера
Shahaduzzaman et al. Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson’s disease
Echeverria et al. Cotinine reduces amyloid-β aggregation and improves memory in Alzheimer's disease mice
RU2657438C2 (ru) Терапевтическое средство или профилактическое средство против деменции
Cynis et al. Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges
JP2012522754A5 (enExample)
SA520411188B1 (ar) جسم مضاد مربوط بالفا - ساينوكلين نشط
Doucet et al. Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles
KR20110011596A (ko) 아밀로이드증의 치료 및 예방
JP2016501247A (ja) 抗Aβ抗体を使用して脳アミロイド斑を減少させる方法
JP2015517502A (ja) 卒中後の神経形成を促進するためのセマフォリン−4d結合分子の使用
JP6611858B2 (ja) D3から誘導されたd−エナンチオマーの新規ペプチド及びその使用
CN104379167B (zh) 用于中风和缺血或缺血性病况的人抗体及其特异性结合序列
Levites et al. A human monoclonal IgG that binds Aβ assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo
Levigoureux et al. Binding of the PET radiotracer [18F] BF227 does not reflect the presence of alpha-synuclein aggregates in transgenic mice
Horikoshi et al. Aβ N-terminal-end specific antibody reduced β-amyloid in Alzheimer-model mice
Wang et al. Intramuscular delivery of a single chain antibody gene prevents brain Aβ deposition and cognitive impairment in a mouse model of Alzheimer’s disease
Li et al. Novel naturally occurring autoantibodies attenuate α‐synuclein pathology in a mouse model of Parkinson's disease
CN101506231A (zh) 筛选具有抗淀粉样蛋白性质的化合物的方法